Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion type Assertion NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_head.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion wasGeneratedBy ECO_0000203 NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion wasDerivedFrom befree-20140225 NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion SIO_000772 21083499 NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion evidence source_evidence_literature NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.
- NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_assertion description "[The primary objective of this first multicenter, prospective, single-blind, dose escalation study was to obtain safety and tolerability information of the iNOS lipoplex (CAR-MP583) gene therapy for reducing restenosis following PCI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP266605.RA55ajwR5eaFihxfhxvPw6izINidyiOmDvQ44kZT0AEj4130_provenance.